Fresenius Medical Care placed a €500 million bond maturing in February 2032, with a 4.250% p.a. coupon and 4.363% p.a. yield. Proceeds will fund general corporate purposes, including refinancing existing financial liabilities; settlement is envisaged for November 16, 2026.
FMS · Fresenius Medical Care AG
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 50%
- Last earnings
- Nov 3, 2026
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Fresenius Medical Care lowered its 2026 operating income outlook to between flat and a negative mid-single-digit percentage and expects total headwinds of 300 to 350 million in 2027 from reimbursement-related and base-business pressures.
Fresenius Medical Care AG said CMS’s final 2027 ESRD PPS sets the base rate at $297.52, up $15.81 from $281.71, and projects 2.7% higher aggregate payments to all ESRD facilities.
Fresenius Medical Care reported third-quarter revenue of EUR 4,937 million, operating income of EUR 384 million, down 19%, and net income of EUR 160 million, down 42%. It narrowed its 2026 operating-income outlook to between flat and a negative mid-single digit percent growth rate.
Fresenius Medical Care AG appointed Shervin J. Korangy CEO and Chair of the Management Board effective October 12, 2026, succeeding Helen Giza; he resigned from the Supervisory Board, and Ann Custin was identified as his successor.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FMS
this stock
Fresenius Medical Care AG
|
$10.61B | -14.2% | +5.9% | — | 0.6% |
|
HCA
HCA Healthcare, Inc.
|
$99.34B | +1.9% | +7.1% | 15.8 | 2.3% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$31.59B | -2.2% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$20.95B | +32.4% | +0.9% | 7.6 | 2.2% |
|
EHC
Encompass Health Corp
|
$13.11B | +25.9% | +10.5% | 20.9 | 3.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 9, 2026
- This year
- 20
Fresenius Medical Care placed a €500 million bond maturing in February 2032, with a 4.250% p.a. coupon and 4.363% p.a. yield. Proceeds will fund general corporate purposes, including refinancing existing financial liabilities; settlement is envisaged for November 16, 2026.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FMS | -7.2% | -9.9% | -0.5% | -9.0% | -14.2% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +1.3% | -0.7% | +8.6% | -0.3% | -15.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.